Fiber and Gut Health on GLP-1 Medications: What to Eat, How Much, and Why It Matters

How common is constipation on a GLP-1 drug?

The labels count it. In the Wegovy 2.4 mg injection trials, 2,116 treated adults were followed for up to 68 weeks: constipation 24% versus 11% on placebo, nausea 44% versus 16%, diarrhea 30% versus 16%, vomiting 24% versus 6% [2]. The Foundayo label reports constipation in 20% at 5.5 mg, 27% at 9 mg and 24% at 17.2 mg, against 9% on placebo [3]. Pooled Zepbound data at 15 mg show constipation in 11% versus 5% [4]. Rates from different trials are not directly comparable [2].

How do the labels handle gastrointestinal effects?

Through the pace of the dose. The Wegovy label starts the injection at 0.25 mg weekly for 4 weeks and steps up every 4 weeks [2], and the Foundayo label starts at 0.8 mg and allows increases no faster than every 30 days, to a maximum of 17.2 mg [3]. Nausea, vomiting and diarrhea were more frequent during Foundayo dose escalation and decreased over time [3].

What the gut-bacteria studies tested

A randomized study of specifically designed isoenergetic high-fiber diets in adults with type 2 diabetes found that fiber promoted a select group of short-chain-fatty-acid-producing bacteria. Participants in whom those bacteria were more abundant and diverse had better improvement in HbA1c, partly through increased GLP-1 production [1]. That study did not involve GLP-1 drugs.

Fiber structure matters. In a dose-response trial of three chemically distinct type-IV resistant starches in healthy adults, different structures shifted microbiome composition and pushed output toward either propionate or butyrate, with the effect plateauing at 35 g a day in that trial [5].

What the labels say to watch for

Gastric emptying. Wegovy and Foundayo both delay gastric emptying, which the labels say can change absorption of oral medicines [2][3].

Volume depletion. Acute kidney injury from volume depletion is a labeled warning for both drugs, and both labels say to monitor renal function in patients reporting reactions that could lead to volume depletion [2][3]. The Foundayo label says the majority of reported events occurred in patients with nausea, vomiting or diarrhea leading to dehydration [3].

Severe GI reactions. In Foundayo trials, severe GI reactions were reported in about 3% of patients on orforglipron versus 1% on placebo, and the label says the drug is not recommended in people with severe gastroparesis [3]. The labels do not say GLP-1 drugs cause gastroparesis [2][3].

Pancreatitis. The labels describe signs of acute pancreatitis as persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [2][3].